156 related articles for article (PubMed ID: 33687908)
1. Feasibility of a Scale-down Production of [
Migliari S; Sammartano A; Scarlattei M; Baldari G; Janota B; Bonadonna RC; Ruffini L
Curr Radiopharm; 2022; 15(1):63-75. PubMed ID: 33687908
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Boss M; Gotthardt M; Scarlattei M; Baldari G; Silva C; Bonadonna RC; Ruffini L
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056858
[No Abstract] [Full Text] [Related]
3. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
4. Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [
Tokgöz S; Boss M; Prasad S; Shah P; Laverman P; van Riel M; Gotthardt M
Methods Mol Biol; 2023; 2592():143-153. PubMed ID: 36507990
[TBL] [Abstract][Full Text] [Related]
5. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
6. 64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats.
Mikkola K; Yim CB; Fagerholm V; Ishizu T; Elomaa VV; Rajander J; Jurttila J; Saanijoki T; Tolvanen T; Tirri M; Gourni E; Béhé M; Gotthardt M; Reubi JC; Mäcke H; Roivainen A; Solin O; Nuutila P
Mol Imaging Biol; 2014 Apr; 16(2):255-63. PubMed ID: 24101374
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study using
Ståhle M; Kytö V; Kiugel M; Liljenbäck H; Metsälä O; Käkelä M; Li XG; Oikonen V; Saukko P; Nuutila P; Knuuti J; Roivainen A; Saraste A
J Nucl Cardiol; 2020 Dec; 27(6):2386-2397. PubMed ID: 30547299
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
9. Automated production of [
Kraihammer M; von Guggenberg E; Hörmann AA; Gabriel M; Decristoforo C
Nucl Med Biol; 2023; 124-125():108381. PubMed ID: 37634398
[TBL] [Abstract][Full Text] [Related]
10. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL
J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
12. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
13.
Boss M; Rottenburger C; Brenner W; Blankenstein O; Prasad V; Prasad S; Coppi P; Kühnen P; Buitinga M; Nuutila P; Otonkoski T; Hussain K; Brom M; Eek A; Bomanji J; Shah P; Gotthardt M
J Nucl Med; 2022 Feb; 63(2):310-315. PubMed ID: 34215672
[TBL] [Abstract][Full Text] [Related]
14. A Specific HPLC Method to Determine Residual HEPES in [
Migliari S; Scarlattei M; Baldari G; Silva C; Ruffini L
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889351
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
16. PET-Based Human Dosimetry of
Boss M; Buitinga M; Jansen TJP; Brom M; Visser EP; Gotthardt M
J Nucl Med; 2020 Jan; 61(1):112-116. PubMed ID: 31519801
[No Abstract] [Full Text] [Related]
17. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O
Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864
[TBL] [Abstract][Full Text] [Related]
19. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
